fludrocortisone + sodium chloride

Treatment Phase 2-VA Office of Research and Development-orthostatic hypotension refers to a specific pharmacological intervention arm within a clinical trial (NCT00108355) conducted by the VA Office of Research and Development. This combination therapy consists of fludrocortisone and sodium chloride (salt) tablets. Fludrocortisone is a synthetic corticosteroid that acts primarily as a potent agonist at the mineralocorticoid receptor, promoting sodium reabsorption and potassium excretion in the distal tubules of the kidney. This action leads to expansion of extracellular fluid volume and increased plasma volume. The concurrent administration of salt tablets provides the necessary sodium load to maximize the volume-expanding effects of fludrocortisone. This treatment is indicated for patients with orthostatic hypotension who remain symptomatic despite non-pharmacological measures such as physical therapy and increased dietary salt intake.

Other names

Treatment Phase 2-VA Office of Research and Development-orthostatic hypotensionfludrocortisone plus salt tablets